Country for PR: United States
Contributor: PR Newswire New York
Tuesday, November 10 2020 - 19:00
AsiaNet
Zymo Research Obtains CE IVD Mark for its Quick SARS-CoV-2 Multiplex Kit
IRVINE, California, Nov. 10, 2020 /PRNewswire-AsiaNet/

  -- Low cost, high-sensitivity diagnostic test for COVID-19 detection

Zymo Research announced today that it obtained a CE IVD mark for the Quick 
SARS-CoV-2 Multiplex Kit in compliance with the Directive 98/79/EC of the 
European Parliament and of the Council of 27 October 1998 on in vitro 
diagnostic medical devices. The Quick SARS-CoV-2 Multiplex Kit ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=1102572270&u=https%3A%2F%2Fwww.zymoresearch.com%2Fpages%2Fquick-sars-cov-2-multiplex-kit%3Futm_source%3DPRnewswire%26utm_medium%3DPress_Release%26utm_campaign%3Dmultiplex_press_release_11.10.20%26utm_content%3DMultiplex_CE_IVD&a=Quick%C2%A0SARS-CoV-2+Multiplex+Kit 
) is a real-time reverse transcription PCR (RT-PCR) test used for the 
qualitative detection of nucleic acids from SARS-CoV-2 (the virus that causes 
COVID-19) in upper and lower respiratory specimens taken from patients whose 
healthcare providers suspect have contracted COVID-19.

Photo - 
https://mma.prnewswire.com/media/1330735/Zymo_Research_Corp_Quick_SARS_CoV_2_Multiplex_Kit_CE_IVD.jpg 

Logo - https://mma.prnewswire.com/media/364743/Zymo_Research_Corp_Logo.jpg
 
The Quick SARS-CoV-2 Multiplex Kit has a limit of detection (LoD) of 10-virus 
copies/reaction and up to 382 samples can be analyzed for each RT-PCR run. This 
high performance, combined with increased throughput, competitive pricing, and 
a widespread distribution network, makes this test among the best on the 
market.* The kit is ideal for clinical diagnostic labs that currently offer or 
want to offer COVID-19 testing including hospitals, universities, research 
centers, as well as laboratories that perform environmental surveillance for 
SARS-CoV-2.

The kit is easy to use in any lab equipped with RT-PCR instrumentation that is 
capable of detecting HEX (or VIC) and Quasar 670 (or Cy5) fluorophores. It 
comes in multiple formats (100-, 1,000-, or 10,000-test quantities), which make 
it amenable for use in small or large laboratories. With a strong international 
distribution network and a high production capacity, Zymo Research is capable 
of meeting the high-volume reagent demands of laboratories around the globe.

"With over 46 million** COVID-19 cases reported worldwide, our goal is to help 
stop the spread of SARS-CoV-2 by enabling increased testing," said Dr. Paolo 
Piatti, Senior Scientist at Zymo Research. "The CE IVD mark, along with the 
competitive pricing, makes this high-quality product readily accessible to 
laboratories and ultimately expands the availability of COVID-19 testing to 
many more facilities throughout the world."

For more information about Zymo Research's Quick SARS-CoV-2 Multiplex Kit and 
workflow, please visit their website ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=1071180385&u=https%3A%2F%2Fwww.zymoresearch.com%2Fpages%2Fquick-sars-cov-2-multiplex-kit%3Futm_source%3DPRnewswire%26utm_medium%3DPress_Release%26utm_campaign%3Dmultiplex_press_release_11.10.20%26utm_content%3DMultiplex_CE_IVD&a=website 
) or contact them via email at covid19requests@zymoresearch.com.

About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific 
and diagnostics community with state-of-the-art molecular biology tools since 
1994. "The Beauty of Science is to Make Things Simple" is their motto, 
reflected in all of their products, from epigenetics to DNA/RNA purification 
technologies. Historically recognized as the leader in epigenetics, Zymo 
Research is breaking boundaries with novel solutions for sample collection, 
microbiomic measurements, diagnostic devices, and NGS technologies that are 
high quality and simple to use. Follow Zymo Research on Facebook ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=2807860661&u=https%3A%2F%2Fwww.facebook.com%2Fzymoresearch&a=Facebook 
), LinkedIn ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=24001963&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzymo-research-corp%2F&a=LinkedIn 
), Twitter ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=3240735431&u=https%3A%2F%2Ftwitter.com%2FZymoResearch&a=Twitter 
), and Instagram ( 
https://c212.net/c/link/?t=0&l=en&o=2976374-1&h=3267328113&u=https%3A%2F%2Fwww.instagram.com%2Fzymoresearch%2F&a=Instagram 
).

References
* 
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data 

**https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-wo
rldwide/

SOURCE: Zymo Research Corp.

CONTACT: Marketing Department, Zymo Research Corp., 949.679.1190, 
marketing@zymoresearch.com
Translations

Japanese